813445-18-0

Upstream product

• 14160-65-7 ethyl 8-oxo-1,4-dioxaspiro[4.5]decane-7-carboxylate 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 121210-56-8 ethyl 8-hydroxy-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate 

Downstream Products

• 1092728-38-5 ethyl (7S,8R)-8-{[(1R)-1-phenylethyl]amino}-1,4-dioxaspiro[4.5]decane-7-Carboxylate hydrobromide 
• 1360464-27-2 C₂₁H₂₆N₂O₄S 
• 1360464-26-1 C₂₁H₂₆N₂O₄S 
• 1360464-25-0 C₂₁H₂₆N₂O₄S 
• 1360464-28-3 C₂₁H₂₃NO₅S 
• 1360464-24-9 C₂₃H₂₇NO₆S 
• 1360464-23-8 C₂₃H₂₇NO₄S 
• 813445-23-7 ((7R,8R)-7-Hydroxymethyl-1,4-dioxa-spiro[4.5]dec-8-yl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Preparation and biological evaluation of conformationally constrained BACE1 inhibitors

Abstract The BACE1 enzyme is a key target for Alzheimer's disease. During our BACE1 research efforts, fragment screening revealed that bicyclic thiazine 3 had low millimolar activity against BACE1. Analysis of the co-crystal structure of 3 suggested that potency could be increased through extension toward the S3 pocket and through conformational constraint of the thiazine core. Pursuit of S3-binding groups produced low micromolar inhibitor 6, which informed the S3-design for constrained analogs 7 and 8, themselves prepared via independent, multi-step synthetic routes. Biological characterization of BACE inhibitors 6-8 is described.

Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2)

We report the synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamides (4) as CCR2 inhibitors for the potential treatment of inflammatory diseases. Several of the compounds display nanomolar binding affinity for CCR2. The in vitro structure-activity

DIHYDRO PYRROLOQUINOLINE DERIVATIVES

A compound represented by the formula (I) wherein A is a benzene ring optionally having substituent(s), R is a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s), X1 and X2 are each

Process of preparing N-ureidoalkyl-piperidines

The present application describes a process of preparing a compound of formula (IV), or salt or stereoisomer thereof: wherein Pg, at each occurrence, is independently selected from an amine protecting group; comprising the steps of reacting a compound of Formula with a reducing agent to give a compound of Formula III: reacting the compound of formula (III) with an amine of formula (IIa) using reductive amination to give the compound of formula (III)

N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

The present application describes modulators of chemokine receptor activity of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheum